• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Gls Share Price

    Glenmark Life Sciences Share PriceGlenmark Life Sciences

    Mid Cap 12.4k Result
    ₹635.6
    -4.7 (-0.73%)
    As on 06 December, 2023 | 03:31 BSE: 543322 NSE: GLSISIN: INE03Q201024

    Glenmark Life Sciences Performance

    Day Range

    • Low 630.35
    • High 649.90
    ₹ 635.6

    52 Week Range

    • Low 370.00
    • High 675.00
    ₹ 635.6
    • Open Price640.10
    • Previous Close640.30
    • Volume79331

    Start SIP in Glenmark Life Sciences

    Start SIP

    Glenmark Life Sciences Share Price

    • Over 1 Month 2.43%
    • Over 3 Month 0.61%
    • Over 6 Month 18.34%
    • Over 1 Year 45.61%

    Glenmark Life Sciences Key Statistics

    P/E Ratio 15.4
    PEG Ratio 0.7
    Market Cap Cr 7,788
    Price to Book Ratio 3.6
    EPS 38.1
    Dividend 6.8
    Relative Strength Index 55.67
    Money Flow Index 56.93
    MACD Signal 1.23
    Average True Range 11.04

    Glenmark Life Sciences Investment Rating

    • Master Rating:

    • Glenmark Life Sciences has an operating revenue of Rs. 2,335.86 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 29% is great, ROE of 21% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 15% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 131 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Glenmark Life Sciences Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 595578621541509490514
    Operating Expenses Qtr Cr 428385415395366343372
    Operating Profit Qtr Cr 167193206145144147142
    Depreciation Qtr Cr 13131211101010
    Interest Qtr Cr 0000000
    Tax Qtr Cr 40475136373839
    Net Profit Qtr Cr 11913514610510710999
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 2,1902,138
    Operating Expenses Annual Cr 1,5191,507
    Operating Profit Annual in Cr 642616
    Depreciation Cr 4238
    Interest Annual Cr 128
    Tax Annual Cr 162146
    Net Profit Annual Cr 467419
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 313598
    Cash from Investing Activity Annual Cr -154-122
    Cash from Financing Annual Activity Cr -388-79
    Net Cash Flow Annual Cr -228397
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 2,1382,054
    Fixed Assets Annual Cr 842687
    Total Non Current Assets Annual Cr 852706
    Total Current Assets Annual Cr 1,8501,765
    Total Assets Annual Cr 2,7022,471
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 175168
    ROE Annual % 2220
    ROCE Annual % 2928
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3130
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Glenmark Life Sciences

    Glenmark Life Sciences Technicals

    EMA & SMA

    Current Price
    ₹635.6
    -4.7 (-0.73%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹630.39
    • 50 Day
    • ₹627.49
    • 100 Day
    • ₹612.67
    • 200 Day
    • ₹575.04
    • 20 Day
    • ₹629.83
    • 50 Day
    • ₹627.75
    • 100 Day
    • ₹629.34
    • 200 Day
    • ₹554.82

    Glenmark Life Sciences Resistance and Support

    PIVOT
    ₹638.62
    Resistance
    First Resistance 646.88
    Second Resistance 658.17
    Third Resistance 666.43
    RSI 55.67
    MFI 56.93
    MACD Single Line 1.23
    MACD 2.37
    Support
    First Resistance 627.33
    Second Resistance 619.07
    Third Resistance 607.78

    Glenmark Life Sciences Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 81,998 4,910,860 59.89
    Week 111,289 8,005,018 71.93
    1 Month 118,760 8,572,097 72.18
    6 Month 219,283 13,172,335 60.07

    Glenmark Life Sciences Result Highlights

    Glenmark Life Sciences Synopsis

    NSE-Medical-Ethical Drugs

    Glenmark Life Scienc belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 2161.22 Cr. and Equity Capital is Rs. 24.51 Cr. for the Year ended 31/03/2023. Glenmark Life Sciences Ltd. is a Public Limited Listed company incorporated on 23/06/2011 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L74900PN2011PLC139963 and registration number is 139963.
    Market Cap 7,788
    Sales 2,336
    Shares in Float 2.08
    No of funds 79
    Yield 6.84
    Book Value 3.64
    U/D Vol ratio 1.7
    LTDebt / Equity
    Alpha 0.13
    Beta 0.68

    Glenmark Life Sciences

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 82.85%82.85%82.85%82.85%
    Mutual Funds 0.38%0.52%
    Insurance Companies 0.15%0.07%
    Foreign Portfolio Investors 4.39%3.27%3.28%4.45%
    Financial Institutions/ Banks
    Individual Investors 9.21%10.02%10.87%9.78%
    Others 3.02%3.34%3%2.85%

    Glenmark Life Sciences Management

    Name Designation
    Mr. Glenn Saldanha Chairman & Non-Exe.Director
    Dr. Yasir Rawjee Managing Director & CEO
    Mr. Vinod Naik Executive Director
    Mr. V S Mani Non Executive Director
    Mr. Sridhar Gorthi Independent Director
    Mrs. Manju Agarwal Independent Director
    Mr. Taruvai Laxminarayanan Easwar Independent Director
    Ms. Gita Nayyar Independent Director

    Glenmark Life Sciences Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Glenmark Life Sciences Corporate Action

    Date Purpose Remarks
    2023-10-20 Quarterly Results
    2023-10-09 Interim Dividend
    2023-07-21 Quarterly Results
    2023-04-27 Audited Results
    2023-03-16 Interim Dividend
    Date Purpose Remarks
    2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
    2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
    2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend

    Glenmark Life Sciences MF Shareholding

    Name Amount(cr)
    Union Small Cap Fund Regular Growth 2,869
    Union Flexi Cap Fund Growth 1,621
    Nippon India Nifty Smallcap 250 Index Fund Reg Gr 719
    Union Tax saver (ELSS) Fund Growth 695
    Union Multicap Fund Regular Growth 618

    Glenmark Life Sciences FAQs

    What is Share Price of Glenmark Life Sciences ?

    Glenmark Life Sciences share price is ₹635 As on 06 December, 2023 | 03:17

    What is the Market Cap of Glenmark Life Sciences ?

    The Market Cap of Glenmark Life Sciences is ₹7787.8 Cr As on 06 December, 2023 | 03:17

    What is the P/E ratio of Glenmark Life Sciences ?

    The P/E ratio of Glenmark Life Sciences is 15.4 As on 06 December, 2023 | 03:17

    What is the PB ratio of Glenmark Life Sciences ?

    The PB ratio of Glenmark Life Sciences is 3.6 As on 06 December, 2023 | 03:17

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.